الفهرس 
HCCOnly 14 pages are availabe for public view
 |  | from | 158 |  |  |
| | | from | 158 | | |
Abstract
Background and Purpose
Hepatocellular carcinoma (HCC) has more interest among other types of cancer as, it is the most common primary tumor of the liver and the second leading cause of cancer related death in the world. The number of deaths annually in HCC is identical to the incidence. sRAGE is a soluble isoform of RAGE, it has a cytoprotective effect against harmful effect of RAGE, through binding of RAGE ligands, it acts as a decoy for RAGE ligands and, therefore, blocks the AGE-RAGE axis. The aim of our work was to assess the diagnostic and predictive value of sRAGE in HCC patients among CLD patients.
Methods Thirty patients with CLD and thirty patients with HCC were subjected to the following: CBC, liver function test, tumor marker (Alfa fetoprotein), ultrasound and triphasic pelviabdominal CT. Thirty Sex and age-matched controls were also recruited
Results, sRAGE was found to be low in CLD patients and much lower in HCC patients with a diagnostic value of it in HCC patients.
Conclusion, Soluble RAGE has a cytoprotective effect through blocking the AGEs- RAGE binding, the hypothesis that soluble RAGE may has a protective effect against HCC with a predictive and diagnostic value within CLD patients is supported by our observation that the serum level of sRAGE was low in CLD patients and much lower in HCC patients.